John A. Davis
The University of Texas MD Anderson Cancer Center · 66 works · 1,669 citations · h-index 16
Top works
- Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice
- Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
- Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
- Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
- Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates
- Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
- Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
- Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements
- NICE guidelines on prostate cancer 2019
- Study of feline oral squamous cell carcinoma: Potential target for cyclooxygenase inhibitor treatment
- Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility
- Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
- In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates
- Cytochrome P450 Architecture and Cysteine Nucleophile Placement Impact Raloxifene-Mediated Mechanism-Based Inactivation
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
- Immunoprecipitation Middle-Up LC–MS for In Vivo Drug-To-Antibody Ratio Determination for Antibody–Drug Conjugates
- BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
- Formation of raloxifene homo-dimer in CYP3A4, evidence for multi-substrate binding in a single catalytically competent P450 active site
- Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
- Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML